Fierce Pharma
FEBRUARY 2, 2024
Mark your calendars, oncology drug and CAR-T therapy developers. | Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.
MedCity News
FEBRUARY 2, 2024
A new era in maternal care is emerging with the advent of maternity care management platforms. Innovative organizations are centralizing the coordination of all patient care aspects, seamlessly integrating with providers’ electronic health records, existing workflows, and health information exchanges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 2, 2024
As AbbVie slogs through sharp revenue declines for Humira, the company is looking to the immunology light at the end of the tunnel. | Sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion in the third quarter.
MedCity News
FEBRUARY 2, 2024
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.
Fierce Pharma
FEBRUARY 2, 2024
In his first earnings call as Bristol Myers Squibb’s CEO, Chris Boerner laid out his plan to quickly navigate the company through a period filled with patent cliffs and new government-man | In his first earnings call as Bristol Myers Squibb’s CEO, Chris Boerner laid out his plan to quickly navigate the company through a transition period filled with patent cliffs and new government-mandated pricing pressure.
Pharmaceutical Commerce
FEBRUARY 2, 2024
A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 2, 2024
Adapting to healthcare consumerism is vital for providers to stay competitive. Shifting from traditional roles to informed consumers requires embracing transparency, technology, and personalized care.
PharmaVoice
FEBRUARY 2, 2024
Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.
MedCity News
FEBRUARY 2, 2024
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
European Pharmaceutical Review
FEBRUARY 2, 2024
Orano Med (a subsidiary of the Orano Group), has begun to build a new manufacturing site for targeted alpha therapies (TAT) for oncology indications. The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. TAT [targeted alpha therapies] is one of the most potent therapeutic payloads against cancer cells” According to Orano Med, TAT is “one of the most potent therapeutic payloads against cancer cells” As such, these trea
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
FEBRUARY 2, 2024
Foodsmart is rolling out its new program that enables doctors to refer their patients to Foodsmart’s dieticians and healthy eating platform, as well as write prescriptions for healthy food just as easily as they might a normal pharmacy prescription. The initiative is being rolled out at Advocate Health, Intermountain Health and Memorial Hermann Health System.
European Pharmaceutical Review
FEBRUARY 2, 2024
A study has described a multivalent-colloid detection system capable of identifying whole genomes of bacteria without the use of DNA amplification. Data from the paper published in Applied Physical Sciences , showed that the method can detect pathogens at an early stage when the bacterial load is low. Currently, the “gold standard” of pathogen identification is based on the recognition of DNA sequences that are unique for a given pathogen, according to the authors.
MedCity News
FEBRUARY 2, 2024
It is critical that we rightsize and redistribute available funds based on our knowledge of persistent cancer disparities to help more patients benefit from potentially lifesaving innovations and ensure no one is left behind.
Copyright Clearance Center
FEBRUARY 2, 2024
The post CCC President & CEO Tracey Armstrong Wins 2024 BIG Innovation Award appeared first on Copyright Clearance Center.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
FEBRUARY 2, 2024
Accompany Health launched Tuesday with $56 million in Series A funding. It offers primary and behavioral care for underserved patients. It also provides social care, such as food, housing and transportation assistance.
PharmaTech
FEBRUARY 2, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
pharmaphorum
FEBRUARY 2, 2024
Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T specialist Kyverna and private rounds for Eyconis, COUR Pharmaceuticals, Basking Biosciences, Enterprise Therapeutics, Halia Therapeutics and NeoPhore.
Pharmaceutical Commerce
FEBRUARY 2, 2024
Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
FEBRUARY 2, 2024
The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosciences’ TYRA-300 for treating achondroplasia.
European Pharmaceutical Review
FEBRUARY 2, 2024
Biogen is planning to reprioritise its resources allocated to ADUHELM ® (aducanumab-avwa), to advance its Alzheimer’s treatment LEQEMBI ® (lecanemab-irmb) and to develop new treatment modalities. The company stated that it will discontinue the development and commercialisation of ADUHELM 100 mg/mL intravenous injection and will terminate the corresponding Phase III ENVISION clinical study.
pharmaphorum
FEBRUARY 2, 2024
Indian pharma Hikma has agreed a $150 million settlement to resolve lawsuits claiming that it helped fuel to the opioid crisis in the US
PharmaTimes
FEBRUARY 2, 2024
Dopamine neuron senescence is a hallmark of Parkinson’s disease
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
FEBRUARY 2, 2024
The PM Society are delighted to be running their fifth Careers Conference that will be taking place on the 21st of February 2024 between 1pm to 6pm at the Royal Society of Medicine. Please share with your colleagues and network, as this is a great opportunity for students to attend and learn more about our industry.
PharmaTimes
FEBRUARY 2, 2024
Individuals with Jewish ancestry are six times more likely to carry a genetic fault
pharmaphorum
FEBRUARY 2, 2024
Virtual opioid use disorder (OUD) therapy provider Bicycle Health has teamed up with telemedicine specialist Talkspace to expand access to care for patients battling addiction in the US. Bicycle Health provides medication for OUD treatment, drug screening, behavioural therapy, and peer support via an app that has been used by tens of thousands of people across the US.
MedCity News
FEBRUARY 2, 2024
One new solution that’s becoming an emerging standard is the Health Payment Account (HPA). HPAs offer employees a line of interest-free credit that employees can use to pay for care expenses up-front.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
pharmaphorum
FEBRUARY 2, 2024
The FDA is due to decide by 4th August whether to approve Adaptimmune’s afami-cel engineered T-cell therapy for advanced synovial sarcoma.
MedCity News
FEBRUARY 2, 2024
Check out news from Alpha Sophia, Wisedocs, Swift Medical, and Isaac Health.
pharmaphorum
FEBRUARY 2, 2024
The World Health Organization (WHO) has said that the burden of cancer on societies around the world is growing at an alarming rate, with a 77% increase in new cases expected by 2050, along with significant gaps in care.
Pharmaceutical Commerce
FEBRUARY 2, 2024
New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
301 
Let's personalize your content